Clinical Trials Using Liposomal Irinotecan

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Liposomal Irinotecan. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-7 of 7
  • Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors

    This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

    This is an open-label, phase 2 comparative study to assess the safety, tolerability, and efficacy of nal-IRI in combination with other anticancer therapies, compared to nab-paclitaxel + gemcitabine, in patients with advanced pancreatic adenocarcinoma who have not received prior chemotherapy. This study will assess the following regimens: - nal-IRI + 5-FU / LV + oxaliplatin - nal-IRI + 5-FU / LV - nab-paclitaxel + gemcitabine The study will be conducted in two parts: 1. a safety run-in of the nal-IRI + 5-FU / LV + oxaliplatin regimen, and 2. a randomized, efficacy study of nal-IRI + 5-FU / LV + oxaliplatin, and nal-IRI + 5-FU / LV, versus nab-paclitaxel + gemcitabine.
    Location: 5 locations

  • TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase I / II trial studies the best dose and how well trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) and liposomal irinotecan work in treating patients with gastrointestinal cancers that has spread to other places in the body or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine / tipiracil hydrochloride combination agent TAS-102 and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Liposomal Irinotecan in Treating Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma

    This phase I trial studies the side effects and best dose of liposomal irinotecan in treating children with newly diagnosed diffuse intrinsic pontine glioma. Liposomal irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Liposomal Irinotecan via Convection-Enhanced Delivery and Magnetic Resonance Imaging with Gadolinium in Treating Patients with Recurrent High Grade Glioma

    This phase I trial studies the side effects and best dose of liposomal irinotecan via convection-enhanced delivery when given together with magnetic resonance imaging with gadolinium in treating patients with high grade glioma that has come back. Liposomal irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may reduce the toxicity of irinotecan to healthy tissues while maintaining or increasing its anti-tumor potency. Convection-enhanced delivery is a method of delivering a drug directly into the brain in order to improve the distribution of the drug throughout the brain. Diagnostic procedures, such as magnetic resonance imaging with contrast agent gadolinium, may help doctors to directly monitor the distribution of liposomal irinotecan within the brain. Giving liposomal irinotecan via convection-enhanced delivery while undergoing magnetic resonance imaging with gadolinium may work better in treating patients with high grade glioma.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

    The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors

    This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
    Location: 2 locations